A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
Michael Warso(University of Illinois Chicago), Tapas K. Das Gupta(University of Illinois Chicago), Linda R. Bressler(University of Chicago), Konstantin Christov(University of Illinois Chicago), Cynthia Schaeffer(University of Illinois Chicago), Jon Richards(Oncology Specialists), D. Majumdar(University of Illinois Chicago), Craig W. Beattie(Abbott (Canada)), Sean Kennedy(University of Illinois Urbana-Champaign), Divya Mehta(University of Illinois Chicago), Tohru Yamada(University of Illinois Urbana-Champaign)
Cited by 182
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis
|Nature Medicine|1995|886
A second-generation linkage map of the bovine genome.
|Genome Research|1997|525
A comprehensive map of the porcine genome.
|Genome Research|1996|480